AEGERION PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell 5,000,000 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to the underwriters (the “Underwriters”) named in Schedule 1 attached to this agreement (this “Agreement”) an option to purchase up to 750,000 additional shares of the Common Stock on the terms set forth in Section 2 (the “Option Stock”). The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock.” This is to confirm the agreement concerning the purchase of the Stock from the Company by the Underwriters.
UNIVERSITY of PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Connecticut
THIS AMENDED AND RESTATED CONSULTING AGREEMENT (this “Agreement”) is dated as of the first day of August 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Scheer & Company, Inc., a Connecticut corporation (“Consultant”). The parties entered into the prior Consulting Agreement on July 1, 2005, and the parties now wish to amend and restate that agreement as provided below.
LICENSE AGREEMENTLicense Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This License Agreement (this “Agreement”), dated as of May 31, 2006 (the “Effective Date”), is made by and between Bayer HealthCare AG, a German corporation (“Bayer”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”). Bayer and Aegerion are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
CONSULTING AGREEMENTConsulting Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS CONSULTING AGREEMENT (this “Agreement”) is dated as of the 4th day of, April, 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Antonio M. Gotto, Jr., M.D., D.Phil (“Consultant”).
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 25th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
INVESTOR RIGHTS AGREEMENT made as of December 15, 2005 (“Investor Rights Agreement”) by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors listed on Schedule I attached hereto (the “Investors”).
